

1/24

FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D




FIG. 2A





FIG. 2B



4/24

FIG. 2C





FIG. 2D



5/24

FIG. 3A

Phase I Diarrhea Score Control





FIG. 3B

Phase I Diarrhea Score Treated



6/24

FIG. 3C





FIG. 3D



7/24

FIG. 4A





FIG. 4B



8/24

FIG. 4C





FIG. 4D



9/24

FIG. 5A





FIG. 5B



10/24

FIG. 5C





FIG. 5D



11/24

FIG. 6A





FIG. 6B



12/24

FIG. 6C




FIG. 6D




FIG. 7A

Phase I Chronicity Score Control





FIG. 7B

Phase I Chronicity Score Treated



14/24

FIG. 7C




FIG. 7D




FIG. 8A

Phase II Chronicity Control




FIG. 8B

Phase II Chronicity Treated




FIG. 8C

Phase II Mean Chronicity Score




FIG. 8D

Phase II Mean Chronicity Score % Change




FIG. 9A





FIG. 9B



18/24

FIG. 9C





FIG. 9D



19/24

FIG. 10A

Phase II Hyperplasia Control




FIG. 10B

Phase II Hyperplasia Treated




FIG. 10C




FIG. 10D




FIG. 11A




FIG. 11B




FIG. 12A




FIG. 12B




FIG. 14A

H3 – heavy chain variable region of CPI-1697

EVQLVESGGGLVQPGGSLRLSCAFSGFTLSISGMIGWVRQAPGKGLEWVA
HWWDDDDKYYNPSLKSRFTISRDTSKNTVYLQMNSLRAEDTAVYYCAR
NYYPYDAWFDYWGQGTLVTVS

FIG. 14B

K1 – light chain variable region of CPI-1697

DIQMTQSPSSLSASVGDRVTITCSASSSINSNHLHWYQQKPKGKAPKLLIYRTSILASGVPSRF
SGSGSGTSFTLTISSLQPEDFATYCYCQQGSNIPFTFGQGTKEIKR